Home / Transcripts / IMCD N.V. (IMCD) · July 29, 2026

IMCD N.V. (IMCD) Earnings Call Transcript

July 29, 2026

Euronext Amsterdam NL Industrials Trading Companies and Distributors earnings 55 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, and thank you for joining IMCD's conference call covering the 2026 half-year results, with CEO Marcus Jordan and CFO Hans Kooijmans hosting. During this opening portion, everyone will be in listen-only mode, and a question and answer session will follow. Should you want to pose a question, simply press *5 on your telephone keypad. At this point I will hand the floor to Marcus Jordan. Mr. Jordan, you may proceed.

Marcus Jordan executive
#2

Thanks so much, Alba. Morning, everyone, and a very warm welcome. I’m Marcus Jordan, and joining me today is our CFO, Hans Kooijmans, to discuss the 2026 half-year results, which came out in a press release earlier this morning. We had a positive first half, with organic growth in both gross profit and EBITA and strong cash conversion. Looking at the business overall in the first half, I’m proud of how our teams handled the dynamic environment, which included most of our suppliers putting through price increases. The size of those increases differed a lot: the larger specialty portion of the portfolio generally saw much lower percentage increases and was less volatile than our smaller semi-specialty component. At IMCD, we’ve been especially careful and responsible in passing on price increases, as we stay focused on long-term partnerships with our customers and suppliers. Moving now to the business from a demand perspective: as Hans and I noted on our last call, we didn’t see any significant pre-buying in Q1, but we did see some at the start of the second quarter. That said, I should note the amount seems to have been relatively limited, since we believe customers learned valuable lessons from post-COVID, when they overstocked and ended up holding high-priced inventory.

Marcus Jordan executive
#3

In the latter part of the quarter, demand was steadier, and so far we haven't observed any meaningful pullback. Across the different markets we serve, our pharmaceutical and Signet business in India, as expected, went back to its usual ordering rhythm in the first half of the year. Food and Nutrition keeps delivering strong results, and in Beauty and Personal Care, demand is broadly stable compared with last year. That's an area we remain focused on, since the technical capabilities and lab infrastructure we have open up good opportunities there. On the Industrial side, the fairest way to characterize the first half of the year for our business is positive, with several encouraging bright spots in areas like medical plastics, wire and cable, and the lubricant market. Some good supplier wins also gave this business a lift. Looking slightly ahead, we're still early in the third quarter, but I can tell you we've had a promising start amid market conditions that remain dynamic. As ever, we have confidence in our specialty-focused and diverse business model. Turning to the 2026 half-year numbers, a summary of our financial results appears on slide four, where we reported gross profit of €658 million, up 7% on a constant currency basis.

Marcus Jordan executive
#4

EBITA rose to €285 million, an increase of 8% on a constant currency basis. I'm pleased to say that free cash flow went up to €222 million, giving us a cash conversion margin of 76.2%, which shows how closely we watch working capital management while also making sure we hold the right inventory to serve our customers on a just-in-time basis. Turning to M&A, slide five shows three acquisitions made in the first half of the year. The first was Dongyang FT in South Korea, a company active in Beauty and Personal Care. Next came Willows Ingredients in the UK and Ireland, a company active in human and animal nutrition. The third, announced at the end of June, is Merit Solutions, which will strengthen our position as a solution provider for the plastics and compounding market in Thailand. On the next slide, some updates on our strategic pillars, where you'll see that we keep expanding the use of AI to support our commercial organization through a number of initiatives, including further development of our sales assistant tool and, more recently, a fully automated pre-visit summary for our sales people that summarizes all the major topics they should cover when visiting or calling their customer.

Marcus Jordan executive
#5

Regarding the people pillar—since people are our greatest asset—we're happy to welcome a global people director onto IMCD's executive committee, and we anticipate collaborating closely going forward so that we keep strengthening our capacity to draw in, cultivate, and promote top talent from inside our organization. During the first half of this year, you'll have noticed a few illustrations of this at managing director level. We announced last year our commitment to setting SBTi near-term targets, and we will be submitting those targets for validation shortly. To wrap up and conclude my portion of the introduction, I think we've executed well during the first half of the year, and I see solid traction on the commercial, operational, and digital excellence initiatives that have been our focus, including supplier development and expansion. Amid these unpredictable times, it matters even more that our sales activity reaches the highest level, that we adapt swiftly when market conditions shift, and that we stay a dependable partner for customers and suppliers alike. Our attention stays on what we can control, and we're committed to delivering long-term growth for our partners and stakeholders in the years ahead. At this point I'd like to pass things to our CFO, Hans Kooijmans, who will bring you an update on the numbers.

Hans Kooijmans executive
#6

Thanks for that introduction, Marcus. Good morning, ladies and gentlemen. I'd like to begin, as always, on page eight of the presentation, where you'll find a summary of the key figures from the press release covering our 2026 first half-year results. As you can see, forex-adjusted revenue rose 11%, combining 3% organic growth with 7% coming from the impact of the first-time inclusion of acquisitions. The forex-adjusted gross profit increase was 7% versus the same period of last year: a combination of 5% resulting from acquisitions and 2% organic. We began the year with a -4% organic growth in the first quarter, followed by a positive 7% organic growth in the second quarter. In that second quarter, every region reported organic gross profit growth. Gross profit as a percentage of revenue was 24.9%, which is roughly 0.7% point lower than last year. It's important to note that more than half of this decrease in percentage came from recently acquired companies, mainly in EMEA, whose gross profit margins are on average lower than those of the legacy IMCD business. We further had the usual impact of changes in product mix, local market circumstances, price, and currency fluctuations.

Hans Kooijmans executive
#7

After that, forex-adjusted operating EBITA rose 8%, driven by a mix of modest organic growth and a positive 7% contribution from acquisitions. As with gross profit, we opened the year at -9% organic growth in the first quarter, and then the second quarter delivered positive organic growth of 11%. Every region posted organic EBITA growth during that second quarter. As we told you on our Q1 call, we faced a fair amount of currency headwind in the first half, both operationally and when translating local currencies into the euro. In the first half, currency translation hit EBITA by -4%, which in absolute terms came to -€12 million. Operating EBITA as a percentage of revenue stood at 10.8%, and the conversion margin was 43.3%, with both only marginally below the same period a year earlier. At the bottom of this slide, you can see that IMCD employs roughly 5,200 full-time people. Versus the end of June last year, we brought in around 150 new colleagues through acquisitions. We kept investing in the quality of our sales and digital teams, and where necessary we rationalized the back office — streamlining the back-office structure — which resulted in a net reduction of about 200 employees.

Hans Kooijmans executive
#8

We were prudent when filling open positions and kept tight reins on expenses, so our own costs showed no organic rise versus a year earlier. After that, net result adjusted for forex and earnings per share both rose by double-digit percentages, and Marcus has already mentioned the strong cash flow, and I'll return to cash flow afterward in this presentation. On page nine, some further detail on how gross profit, EBITA, and conversion margin developed year on year for each operating segment, where the differences, as you can see, are broken out into organic, acquisition, and currency effects. EMEA, in the first column, was clearly the strongest segment during the first half-year. Organic gross profit growth was flat in the first quarter, then came 11% growth in the second quarter, producing the 5% reported. The decline in gross profit margin for this segment, from 27.5% to 26.7% this year, was entirely M&A-related. If you normalize for the effect of recent acquisitions, the average gross profit margin would have come in slightly above last year. Much the same pattern applies to organic EBITA growth in EMEA: -4% in Q1 was followed by a very strong 20% organic growth in the second quarter, yielding 7% organic growth across the first six months.

Hans Kooijmans executive
#9

The EBITA margin held steady at 11.7%, while conversion margin came in slightly better at 43.6%. As you may recall, in the Americas we began the year softly, with organic gross profit and EBITA growth both substantially negative during the first quarter. We're pleased to note an improvement in the second quarter, though it remains modest, with organic gross profit and EBITA growth reported in the low single digits. That second-quarter organic growth did not suffice to offset the Q1 decline, so the first half of this year ended with negative organic growth along with lower EBITA and conversion margin. Turning to Asia-Pacific, following a low single-digit organic decline in gross profit and EBITA in Q1, the second quarter looked considerably healthier, posting positive mid-single-digit organic growth. Operating EBITA and conversion margin were roughly in line with last year, and this segment remains the group's strongest performer. Holding costs, shown in the final column, came in below last year's level at 0.6% of revenue versus 0.7% a year ago. That reduction stems partly from lower costs and partly from greater cost recharges to the operating segments. Moving to page 10, you'll find a summary of the P&L lines from operating EBITA down to the net result for the period.

Hans Kooijmans executive
#10

The net result comes in at €12 million, which is 10% above the prior-year period. Lower finance costs offset the higher income tax expenses. Amortization of intangible assets went up because of acquisitions completed, and these are non-cash costs tied to amortizing supplier relations, distribution rights, and other intangibles. One-off costs are then €6 million below last year, and within this line we booked a €4 million gain on a warehouse sale as a profit, plus somewhat lower costs for acquisitions and one-off adjustments to the organization. Page 11 gives a breakdown of net finance costs. As you can see, the main drivers behind the reported decline are lower changes in deferred considerations, which worked as a negative, and lower currency exchange results, which worked as a positive. Currency exchange results are the realized and unrealized outcomes of translating the monetary assets we hold in foreign currencies into local currencies. The IFRS hyperinflation adjustment then relates to IMCD Turkey. Page 12 summarizes the IMCD balance sheet, and most lines show little change versus the year-end 2025 figures. Property, plant, and equipment — the real fixed assets we own — remain relatively low thanks to the asset-light business model.

Hans Kooijmans executive
#11

About €2.5 billion in total is what intangible assets plus the associated deferred tax liabilities come to, and that stems from acquisitions we've made since July 2014 as well as from our background as a company previously held by private equity. Turning to financing, debt stands at €1.6 billion — I'll return to that shortly — alongside €2.1 billion of equity. That sizable equity stake accounts for 58% of the capital we employ. Moving to Page 13, which summarizes reported working capital. At the close of June, total working capital came in at slightly above €1 billion, roughly 10% higher than December 2025 and €66 million above the figure for June last year. The rise overall reflects a mix of things: the effect on working capital from acquisitions completed, some currency movement, and certain operational developments. Versus December, the increase follows the normal pattern seen through the year and is chiefly driven by larger debtor balances, which come from higher sales in June than in December. If we express working capital in days of revenue, we reported 70 days at the end of June this year, against 69 days at the end of June 2025. At the bottom of this slide, you can see how the days have developed for the three working capital components that matter most.

Hans Kooijmans executive
#12

The rise in debtor days, from 60 last year to 68 this year, comes primarily from significantly stronger sales in this year's second quarter versus the same period a year ago. Back in June last year, as I explained to you, those 54 days of stock were fairly elevated. You may recall that I mentioned at the time how external and internal factors were having a negative impact, and last year we discussed items such as the Red Sea issue, customers pushing back delivery dates because market conditions were changing, like tariffs, and the corrective measures we took to bring down stock levels across various segments. This year, the relatively high stock days figure is a more positive one. As Marcus mentioned, we got off to a promising start in Q3, where current stock levels are needed to cover demand from our customers. On the next slide, you'll find a summary of our net debt position, leverage ratios, and the maturity profile of our debt. Net debt in the first six months was more or less stable at €1.6 billion. During the first six months, we spent about €50 million on acquisitions, paid a dividend of €107 million, and generated healthy cash flow. The leverage ratio at the end of June, based on IFRS and our loan documentation, was 2.8 times EBITA.

Hans Kooijmans executive
#13

That amount stayed nicely under the ceiling our loan documents allow. Since we typically generate cash in the latter half of the year, depending on what acquisitions we pursue, leverage should decline. Over on the right-hand portion of the slide, our debt maturity profile is shown. Let me wrap up this brief recap with a look at cash flow, which is on page 15. Free cash flow came to €222 million, up €49 million from the comparable period a year earlier. Driving that gain were stronger operating EBITA along with reduced working capital investments. CapEx of roughly €3 million came in below what we spent last year and went mainly toward IT investments, some office improvements, and lab equipment. And finally, on page 17, the outlook for this year is laid out. I imagine everyone has already gone through the text in our press release, so I won't read it out loud again. I'd like to give it back to Alba, our operator, so the lines can be opened for Q&A.

Operator operator
#14

Thanks a lot. Ladies and gentlemen, we're ready now to take your questions. If you'd like to ask one, just press *5 on your phone keypad. Our first question is from Suhasini Varanasi at Goldman Sachs. Please go ahead.

Suhasini Varanasi analyst
#15

Good morning, and thanks for taking my questions. I have a couple, please. On 2Q, a very healthy improvement. Could you give some color on pricing versus volume trends? Would you say most of the growth was pricing-led, or did you also see volume improvement? Within this, you had indicated some pre-buy at the beginning of the quarter. Is it possible to quantify that? Is it something that benefited maybe EMEA growth in particular? Then the last one, please. You've indicated a promising start to 3Q. Would you say that trends are probably broadly similar to the second quarter at the beginning of 3Q, or any variances by region? Thank you.

Marcus Jordan executive
#16

Good morning, and thanks for the questions. When we examine the second quarter and consider how pricing compared with volume effects, I believe a range of different elements truly powered the organic growth you observed in Q2. Pricing certainly provided some tailwinds, but as I noted in my earlier remarks, the larger pricing impacts, the ones with bigger percentages, were heavily concentrated in the smaller portion of the portfolio — let's call it the semi-specialty, semi-commodity piece. Within our larger specialty component, those percentages were far, far smaller: single-digit percentages. While an effect existed there, it was only one element. On the volume side, I think it's reasonable to state that we picked up some market share in the more semi-specialty, semi-commodity area, where availability out of Asia-Pacific in certain more remote locations, I'd say, grew thinner. Two other elements, I would argue, were just as significant. First, I sense that our teams are performing especially well. Second, I sense that we enjoy very solid levels of commercial activity. As Hans and I noted, I believe, on the last couple of calls, we strengthened the commercial teams quite substantially during Q4 of last year and the start of this year, and we're very pleased, I'd say, with the higher level of commercial activity that we're seeing.

Marcus Jordan executive
#17

And connected to that, as I noted in the commentary as well, we’ve started to see some good supplier wins come through.

Suhasini Varanasi analyst
#18

Understood. Thanks.

Hans Kooijmans executive
#19

The promising start?

Suhasini Varanasi analyst
#20

Yes.

Marcus Jordan executive
#21

A promising beginning, I'd say. As for Q3, at this point that's really all we can offer. Market conditions remain quite dynamic. Our attention is squarely on what's within our control. We'll see how the quarter unfolds, but as I mentioned, the start has been promising.

Suhasini Varanasi analyst
#22

Thanks a lot. Apologies — let me just put the EMEA part differently, since the strength there stood out as unusually high next to the other regions. Would you call that an underlying strength, or is it more of a one-off tied to the geopolitical conflict? I think that would help us understand how trends should evolve in the second half of the year. Thank you.

Marcus Jordan executive
#23

I'd say it's reasonable to describe EMEA as the steadier market from our vantage point. There's also something to be read into the supplier win element I brought up — of the three regions, that's likely where the biggest effect shows up. And turning to the other side, looking at North America, I'd call that a market too that's been relatively shielded and set apart from matters such as the price increases. There's a difference you'll notice as well, with somewhat more, I'd argue, of a pricing tailwind coming from EMEA and comparatively less from where North America sits.

Suhasini Varanasi analyst
#24

Much appreciated.

Operator operator
#25

Our next question is from Anil Shenoy at Barclays. Go right ahead.

Anil Shenoy analyst
#26

Morning Marcus, morning Hans, and thanks for taking my questions. I have just two, please. First, on cost development: Q2, this quarter, marked the first time in four quarters that positive operating leverage has shown up—meaning EBITA organic growth came in above gross profit organic growth. On your 2Q '25 call, you mentioned that some costs had been built up in the system in anticipation of 4% to 5% gross profit growth, which didn't materialize, and that's why negative leverage has been visible for the last four quarters. What I'm trying to understand is whether the business has now reached a scale at which those earlier cost investments are fully leveraged. Can we expect this positive operating leverage to carry on into H2? That's my first question. My second question concerns Americas. In your Q1 call, you pointed to a substantial organic decline in Americas driven by a volatile business mix. Since you've now reported 2% organic growth in both gross profit and EBITA, perhaps you could give some color on whether the American business has stabilized and what the outlook is for Americas for the rest of the year, please?

Hans Kooijmans executive
#27

Let me take the cost question, if I may. The figures we're reporting today show a cost structure that's roughly flat versus last year. What we've done is, first, we reinforced the sales organization, as Marcus mentioned, since it matters a great deal to be present in the field with the right people on the road, both to grow the business further and to handle the new suppliers we've brought on board. Meanwhile, across recent years we've built plenty of digital tools that help the sales force, and that likewise lets us run our back-office infrastructure far more efficiently. On a net-net basis, that gave us a somewhat smaller headcount, along with a shift in the mix of people. At the same time, I'm hoping to report a modest cost increase at year-end, because we had to pay out larger bonuses as people hit their targets. You may recall that during the last two years we struggled with our results. That likewise meant savings on the bonus side, and come year-end I hope to be saying that, unfortunately, my costs went up somewhat, though the reason is that we enjoyed a fantastic year and paid somewhat more in bonuses.

Hans Kooijmans executive
#28

Up to now, our setup can handle a higher volume of sales than what we currently have, thanks to all the digital advancements and thanks to the extra sales staff we brought on during the first six months.

Marcus Jordan executive
#29

Thank you, Hans. Moving to the question about the Americas — as a reminder, we naturally faced a very difficult comparison in Q1, when Q1 2025 organic growth came in at 21%. As I said earlier, looking at the US, the North America picture differs somewhat from what we observed in other parts of the second quarter, where pricing effects, let's say, arrived later and were more subdued. Compared with other regions, I think we also saw somewhat less pre-buying. And as we've noted previously, in the US in particular we have a bigger industrial component, especially in coatings and construction, and within that space in the US the market remains quite weak. As you mentioned, Q2 performance was better, yet we're still not where we want to be. We've recently strengthened the management team in the region quite substantially, essentially to make sure we fully capture the opportunities that are definitely there for us. We still see plenty of opportunity for the region. Again, our focus is on what we can control, and I feel we're on a better track toward delivering the growth numbers we expect going forward.

Anil Shenoy analyst
#30

Thanks a lot. That really helps.

Operator operator
#31

Annelies Vermeulen from Morgan Stanley has the next question. Go right ahead.

Annelies Vermeulen analyst
#32

Morning Marcus, morning Hans. Two questions from me, if I may. First, in one of your earlier responses I believe you mentioned that you'd observed somewhat tighter availability in APAC and picked up some share, especially on the semi-specialty side, you said, because of that. Could you say a bit more about whether supply problems are showing up anywhere else, any kind of supply constraints coming out of the Middle East, and how that has produced share gains in other parts of the portfolio, and how things are tracking on that front so far in Q3? Second, on the balance sheet only, I think you said before that you'd anticipate a working capital improvement as the year goes on, but with the growth improvement we've seen and assuming it persists and the inventory you need in order to cover demand, how do you now expect working capital to move through the second half? Thank you.

Marcus Jordan executive
#33

Morning, Annelies. Regarding availability, overall I’d say we haven’t been hit especially hard by supply problems up to now. That said, it’s accurate to note that we’ve encountered pockets, and honestly I’d describe them as fairly widespread. I wouldn’t point to any single region where we’ve been especially affected. Again, I’d characterize the effect in the second quarter as not very material, though there were some pockets. Hans, turning to working capital?

Hans Kooijmans executive
#34

Regarding the balance sheet and working capital, Annelies, I basically don't anticipate significant shifts in the days count—that's what I'd call it for each component. There will be some fluctuation depending on what happens with revenue. Should revenue rise, my debtor position rises as well. Across the year, we have the usual pattern where Q2 and Q3 are consistently the peak points in the cycle, since our largest revenues always land in Q2 and Q3. As we approach year-end, we typically observe a decline in working capital amounts. I don't expect that pattern to shift this year. I hope to be able to tell you that we put a lot into debtors thanks to strong sales. It's somewhat like the bonus matter. That is, yeah, the outcome of extra activities, and I'd be glad to share that with you should it occur.

Annelies Vermeulen analyst
#35

Fingers crossed. Thanks to you both. Just to build on that first section, Marcus — you mentioned that availability wasn’t material in the second quarter, but do you expect anything to shift during Q3, maybe as later effects from some of the Middle East issues begin showing up among suppliers, or is it stable right now?

Marcus Jordan executive
#36

Right now, I'd call it stable. As we entered the third quarter, we really haven't seen any difference from Q2. Naturally, as I said earlier, market conditions are dynamic, so let's wait and see what happens, but yes, so far I'd describe it as stable.

Annelies Vermeulen analyst
#37

Great. Thank you. I realize this is a moving target. Thank you.

Marcus Jordan executive
#38

Thanks.

Operator operator
#39

Our next question is from David Kerstens at Jefferies. David, the floor is yours.

David Kerstens analyst
#40

Morning, gentlemen. I have two questions, please. Regarding the pricing tailwinds you mentioned, would you say they peaked in the second quarter, or will there be an ongoing effect during the second half of the year? Will inflation stay elevated for a longer period? Marcus, I believe you referred to the lagged effect of that inflation in the Americas. Also on inflation, the biggest impact was on the semi-commodity side. Beyond the higher prices, does that also reflect less intense competition from Chinese suppliers in markets like Brazil and Southeast Asia? My second question concerns M&A. You mentioned three acquisitions. I believe you spent €50 million. That appears to be the lowest level since 2020. How do you view the M&A market right now? Thank you very much.

Marcus Jordan executive
#41

Good morning, David. On the pricing tailwinds—yes, I'd say what we observed in Q2 was that the count of increases was especially elevated early in the quarter, and then, I'd say, it moderated somewhat. I'd say pricing is still a dynamic market right now, very much tied to what's going on with the conflict. I think it's fair to say things have generally gotten a bit quieter as we moved through the later portion of Q2. On easing competition from China, I think it's fair to say that in certain more remote countries such as Brazil, during the second quarter we did see reduced competition on the semi-specialty, semi-commodity side. And possibly later in the quarter, perhaps some of that Chinese competition was directed more toward the Asia-Pacific market as well. Again, that side is quite dynamic, and again, it's really a matter of the commercial teams staying very focused and adjusting as quickly as they can and as they need to. On the M&A side, I'm very pleased with the three very important acquisitions we completed in the first half of the year, even though they were quite small.

Marcus Jordan executive
#42

Since we don’t set a target for either the value or the amount we spend on acquisitions, or for the number, I think that’s incredibly important, because we need to stay, as we always have been, very laser-focused on acquiring only those companies that are a good strategic fit and that we’re confident will accelerate our organic growth. We still have a healthy pipeline, but it’s fair to say that discussions on the acquisition side are taking longer during these dynamic market conditions. We are definitely not being impatient, and it’s also a matter of us gaining confidence that we’re paying the right price for the acquisition.

David Kerstens analyst
#43

Thanks, Marcus — that’s very clear.

Marcus Jordan executive
#44

Thanks.

Operator operator
#45

Our next question is from David Symonds at Exane BNP Paribas. Please go ahead.

David Symonds analyst
#46

Thanks so much. I have a couple of questions, if I may. First, on Signet, could you tell me how things went during the second quarter? I recall you mentioning some green shoots there. I'm aware that the comps for Signet become easier in the second half of the year, but I'm just wondering whether in Q2 we're flat versus a year earlier, down, up, or how that business is generally trending. Second, you noted, of course, that the pricing was concentrated in the semi-specialty portion of the business. Just to get a different perspective on the dynamic in the second quarter, do you think specialty earnings were higher year-on-year? Or was it simply a semi-specialty contribution? Thank you.

Marcus Jordan executive
#47

Good morning. First, as I said at the start, we've observed across the pharmaceutical market generally — if you remember, Q4 of last year was a fairly exceptional period for us — and we did expect the normal, let's say, ordering pattern and performance to return in the first half, and that's what we've seen. The Signet business, I'd say, has tracked pretty much the same trend, with nothing exceptional there. On pricing, David, I think it's worth reiterating that my point was that the semi-specialties, partly since they're typically lower price products, saw greater percentage increases than the specialties. That isn't to say we didn't get price increases on the specialty component of the portfolio, but as a percentage, it was quite a bit lower. Does that answer your question there?

David Symonds analyst
#48

Yes, it does. Thank you so much.

Marcus Jordan executive
#49

Thanks.

Operator operator
#50

Our next question is from Nicole Manion at UBS. Please go ahead.

Nicole Manion analyst
#51

Morning, and thanks for taking my question. Could you expand a little more on those supplier wins on the industrial side, and perhaps on what you're generally seeing across the group when it comes to landing these new mandates? Has the uptick here been at all opportunistic, driven by the environment, or would you describe it instead as more a reflection of longer-term work to engage some of these new suppliers? Thanks.

Marcus Jordan executive
#52

I won't get into details, but what strikes me as most encouraging is that this isn't concentrated in a single market. As an organization, over roughly the past 12-plus months, we've really sharpened our emphasis on what we do from a commercial excellence standpoint. We built up the team — as Hans and I noted, commercially, at the end of last year and into the start of this one — and our reputation plus delivering on our promises carries a lot of weight. My view is that we've long held a very solid reputation in the market. With suppliers, I sense that nearly doubling down — through a challenging economic climate — on the sales organization and the infrastructure we have has landed especially well. I also think suppliers broadly are going through a fairly rough stretch, so they're taking a harder look at their own organizations, asking what sales organization they need on a fixed-cost basis and what percentage of their business they then outsource. On a couple of earlier calls, I've said that we've been having, I'd describe it, increasingly positive conversations. This, I believe, marks the first time we've spoken proactively about the wins.

Marcus Jordan executive
#53

I'd say it's a real pleasure, and it reflects well on the entire team, that we've actually managed to convert those, or at least a portion of them.

Nicole Manion analyst
#54

Thanks, that's really useful.

Marcus Jordan executive
#55

Thanks.

Operator operator
#56

We'll take the next question from Luuk van Beek at Degroof Petercam. Go ahead, please.

Luuk van Beek analyst
#57

Good morning. Two questions, if I may. First, on those low inventory levels at customers and what just-in-time delivery demands — does that mean you'll have to adjust anything on your side, whether in stock levels, logistics, or elsewhere? Second, regarding how the price increases affect volumes, and more broadly the cost inflation we're seeing around the world: are there any signs that customers are turning more cautious about volumes as a result of this global cost inflation?

Marcus Jordan executive
#58

Morning, Luuk. Regarding just-in-time, I believe we've discussed this on essentially every call over the past two years — customer behavior being what it is, given volatile or dynamic market conditions, just-in-time delivery has become, I'd say, more of the norm. I wouldn't claim we've witnessed dramatic shifts in order patterns, but as a distribution company — and we keep repeating this — it is absolutely our job to hold inventory so we can serve those customers, and also to capitalize on, let's say, market conditions where, amid the uncertainty, we function as an inventory backstop for them. On the volume impact from price increases, as I said in my preamble, we've been very careful about the level of price increase we pass on, and we work hand in hand with our suppliers to ensure we don't destroy demand over the longer term. It could have happened that during this uncertain period we pushed through very large, excessive price increases, but that isn't the case. As a company, we truly focus on the long-term future, the relationships we have with customers and suppliers, and being very cautious alongside our suppliers when it comes to minimizing as much as possible the price increase that we pass through.

Luuk van Beek analyst
#59

Got it, thanks.

Operator operator
#60

Up next, we have a question from Eric Wilmer at Kempen. Eric, the floor is yours.

Eric Wilmer analyst
#61

Morning Marcus and Hans, and thanks for taking my questions. I also had a question about the Americas, where organic sales growth looked a bit more modest in Q2 than in the other divisions. Given its skew toward semi-specialty and the less intense Asian competition you point to in the region, I'd assume Latin America probably did relatively well on both pricing and volume. Would that imply somewhat negative volumes in North America? Then another question: to what extent are you now seeing some customers potentially come back across your portfolio in general — customers that were potentially less willing to buy when prices first started to peak back in March and April and at some point simply have to return? Then a last question: I was wondering if you could also walk us through what you're roughly expecting in terms of cash out later this year and next year for previously announced M&A, including, for example, earnouts? Thank you.

Marcus Jordan executive
#62

Thanks for those questions, Eric. When we turn to the Americas, please don't underestimate how large the coatings and construction market is in that region. What we're really waiting for there, unfortunately, is interest rates coming down, so that the housing space sees more of a dynamic move. And yes, as I said earlier, it's fair to say we've picked up additional business on the semi-specialty side, but we also shouldn't overestimate what percentage of the region as a whole that represents. In certain pockets, the percentage is greater. Brazil is the country I've mentioned before, and it's fair to say we did gain some market share during the second quarter. As for negative volumes in North America, I don't think we've seen that. What we have seen from a North America perspective, I think, is a bit of a delay, but also a much more muted level from a price increase standpoint — both in terms of how many increases we've seen and certainly the percentage amount of the increase. As for customers returning now, we did see some pre-buy at the start of the quarter, as I mentioned.

Marcus Jordan executive
#63

That didn't strike me as significant, in my view. Most of it would have been worked through during the second quarter, I believe. Again, the promising start to Q3 lets you read into that — there isn't much volatility, I would say, from a month-to-month perspective that we've seen so far.

Hans Kooijmans executive
#64

Should I mention deferred considerations? Marcus?

Marcus Jordan executive
#65

Yeah.

Hans Kooijmans executive
#66

Eric, I believe what we disclosed was that at the close of last year, we had roughly €40 million in deferred considerations on our balance sheet. In the press release we put out, you can see that out of that 40, we paid approximately 18, and we added around 5 to the deferred consideration because of recent acquisitions. The balance within my total debt position is fairly small right now. I hope that answers it. You can find the details on page 23 of the press release.

Eric Wilmer analyst
#67

Thanks, both of those answers were really useful.

Operator operator
#68

Our following question is from Quirijn Mulder at ING. You have the floor.

Quirijn Mulder analyst
#69

Morning. I'll keep myself to a pair of questions. Hans, last year we talked about the coast-to-coast supplier streamlining, as I'd put it. Is that effort still underway, and in your view did it have any effect during the second quarter in the US? The second one concerns tariffs. With one year of tariffs behind us, is there anything specific you can say regarding how they affected, let me say, the second quarter? Perhaps also something on repayments or that kind of thing? Could it be that you receive some repayments from the government owing to, as I'd put it, the policy change there?

Marcus Jordan executive
#70

Thanks for those questions, Quirijn. Regarding supplier streamlining in the US, that work continues. I'd say there's nothing really exceptional to report for Q2. As for tariffs, yes, that remains a live topic, but once again, nothing material came up in Q2. On repayments, we're in the middle of recovering those sums and then being in a position to hand them back to customers. As a reminder there, the vast bulk of what we do in the US follows a local-for-local model. The tariff refund amount, let's say, is in fact fairly modest.

Hans Kooijmans executive
#71

We returned that to customers as well.

Marcus Jordan executive
#72

Yeah.

Quirijn Mulder analyst
#73

All right, thanks.

Operator operator
#74

Tristan Lamotte of Deutsche Bank has the next question. Go right ahead.

Tristan Lamotte analyst
#75

Hello, and thanks for the questions. First, could you give us some color on the pipeline and how much innovation activity is happening? A few of your producers have mentioned an uptick in innovation, so I'm curious what trends you're seeing and whether that is showing up in organic growth yet. Second, I'm a little worried that a fair amount of this improvement is temporary, given how big the swing is in organic growth from Q1 to Q2 and in conversion margin — to be specific on conversion margin, it went from 41.6% in Q1 to 44.9% in Q2. Could you walk through which elements you view as temporary and which look more permanent? Thank you.

Marcus Jordan executive
#76

Thank you very much. Regarding the pipeline and how innovation is trending, I believe I've noted during the past two calls just how active our labs are. Our emphasis is squarely on ensuring that the work we take on produces gross profit. We are certainly seeing substantial momentum when it comes to how many projects are moving through the lab, and also in terms of conversion. That is among the genuine strengths and foundational pillars that we at IMCD possess, and I think our reputation is solid — customers turn to us for formulary expertise, seeking not just individual ingredients but guidance on formulations as well. Yes, I would say that remains a hugely important pillar and, I would add, a driver of gross profit growth going forward. On your question about the temporary change, Tristan, I think it's once more a situation where nobody can predict what lies ahead. I believe we executed well during the first half of the year. We concentrate on what is within our control, which I've referenced previously. Let's wait and see what comes next. Again, given the level of sales activity, which we've observed rising, and the relationships we maintain with customers and suppliers alike, I feel we're on a good path.

Marcus Jordan executive
#77

Sadly, none of us owns a crystal ball that lets us see what lies ahead.

Tristan Lamotte analyst
#78

Much appreciated.

Marcus Jordan executive
#79

Once more, Q3 has gotten off to a promising beginning, so we'll see.

Tristan Lamotte analyst
#80

Thanks a lot. Appreciate it.

Operator operator
#81

Our last question is from Chetan Udeshi at JPMorgan. Please go ahead.

Chetan Udeshi analyst
#82

Hello, good morning, and thank you for the opportunity to ask questions. First, I'd like to direct one to Hans. Looking at the cash flow statement, your cash taxes in H1 appear pretty low relative to last year and also compared with what I had in my model. I'm curious whether there's been some structural change, or whether this is simply phasing between H1 and H2 that led to much smaller cash tax payments. My second question goes back to your remark, Marcus, about pre-buying being very limited, and I'm trying to reconcile that with gross profit in the second quarter being up roughly 12%, as I recall, versus Q1. There is some seasonality from Q1 to Q2, with Q2 generally rising, but not to the degree we saw in Q2. If pre-buying hasn't been significant, how do you reconcile that sharper second-quarter increase, since overall end demand doesn't seem to have shown any genuine improvement?

Hans Kooijmans executive
#83

Chetan, on the tax front, essentially the tax gets paid at the point it falls due in the countries where we generate profit and owe taxes. I also noticed that during the first six months, the tax burden in the P&L was, I believe, higher than a year earlier, consistent with improved results. Tax cash out was, I think, roughly €10 or €12 million below the same period last year. This is purely a timing matter. When payments get made and in what amount? That isn't something we control. It hinges on when local tax authorities act. Certainly, the tax we accrue and that you see running through the P&L at a given moment has to be paid. More of a timing issue. Yeah.

Marcus Jordan executive
#84

Regarding the pre-buy and gross profit growth, we don't have exact visibility into what customers are purchasing or how much inventory they're holding, but honestly, we haven't observed anything abnormal in the order book, I'd say. As I mentioned, there's been considerable stability when you look at it month to month, and that leads us to conclude that pre-buying wasn't significant. Now, on gross profit growth, as I said earlier, I think it comes from a combination of things — the pricing tailwind contributes a component, but there's also the execution side, which I believe we've handled well, along with the supplier wins. It really is those factors working together, and pinning down precisely how much comes from each one is difficult. Again, I take comfort in the fact that we haven't seen large fluctuations on a month-to-month basis.

Chetan Udeshi analyst
#85

Understood. Thank you.

Marcus Jordan executive
#86

Much appreciated.

Operator operator
#87

I'll now turn the floor back to Mr. Jordan for any closing remarks.

Marcus Jordan executive
#88

Thanks, Alba, and to everyone for being on the call this morning and for your questions. We hope you all enjoy the rest of the summer. Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete IMCD N.V. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to IMCD N.V. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.